Drug Profile

Mizagliflozin - Vogenx

Alternative Names: KWA 0711

Latest Information Update: 18 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Kissei Pharmaceutical
Developer Kissei Pharmaceutical; Vogenx
Class Amides; Antihypoglycaemics; Laxatives; Pyrazoles; Small molecules
Mechanism of Action Sodium-glucose transporter 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase II Hypoglycaemia
Phase I Gastroparesis
Preclinical Unspecified
Discontinued Constipation

Most Recent Events

18 Jun 2025 Phase-I clinical trials in Gastroparesis in USA (PO) (Vogenx pipeline, June 2025)
18 Jun 2025 Preclinical trials in Undisclosed rare disease in USA (PO) (Vogenx pipeline, June 2025)
01 Oct 2019 Chemical structure information added

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com